Rosetta Genomics, Ltd. (NASDAQ: ROSG), an innovative molecular diagnostics company, utilizes microRNAs, a collection of recently discovered non-coding control genes, to develop a broad array of tests for cancers and women’s health indications. These non-coding genes have demonstrated to be highly sensitive and tissue specific biomarkers. The company’s early recognition of microRNAs’ vast potential has led to great discovery and has the establishment of a leading intellectual property (IP) portfolio. For further information, visit the Company’s web site at www.rosettagenomics.com.
- 17 years ago
QualityStocks
Rosetta Genomics, Ltd. (NASDAQ: ROSG)
Tags Rodman & Renshaw
Related Post
-
TechForce Robotics (NGTF) Secures Full Ownership of BIM-E IP, Bolstering Robotics Ecosystem Amidst an Industry Transition
TechForce Robotics announced that the company has secured full ownership of the Intellectual Property for…
-
Renewal Fuels Inc. (RNWF) Strengthens Leadership Bench and IP Strategy as It Drives New Approach Toward Commercial Fusion Energy
Renewal Fuels is repositioning itself as an infrastructure-focused fusion energy company following its merger with…
-
Liora, a subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy
There are several types of technologies for treating tumors with proton therapy, such as pencil…